Arrowhead Pharmaceuticals (ARWR) vs Supernus (SUPN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Arrowhead Pharmaceuticals (ARWR) has outperformed Supernus (SUPN) over the past year, gaining 2.3% versus a loss of 36.9%. Over five years, SUPN leads with a -6.5% price change compared with -42.6% for ARWR. Supernus is the larger company by market cap ($5.94 billion vs $5.85 billion), about 1.0 times the size.
Supernus converts more of its revenue into profit, with a net margin of -5.4% versus -160.6%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ARWR | SUPN |
|---|---|---|
| Share price | $41.37 | $28.61 |
| Market cap | $5.85B | $5.94B |
| 1-day change | -5.22% | +0.92% |
| YTD return | -37.69% | -42.43% |
| 1-year return | +2.27% | -36.87% |
| 5-year return | -42.56% | -6.53% |
| Forward P/E | — | 7.15 |
| EPS (TTM) | $-5.11 | $-0.76 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $450.82M | $718.95M |
| Revenue growth (YoY) | -45.65% | +8.63% |
| Net income (latest FY) | $-724.21M | $-38.55M |
| Gross margin | — | 89.63% |
| Operating margin | -156.86% | -8.66% |
| Net margin | -160.64% | -5.36% |
| 52-week high | $95.49 | $42.81 |
| 52-week low | $40.43 | $25.92 |
| Distance from 52-week high | -56.68% | -33.17% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +156.39% | +89.23% |
| Average volume | 2.08M | 2.77M |
| Shares outstanding | 141.37M | 207.72M |
| Employees | 1,062 | 827 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ARWR has outperformed SUPN by 39.1 percentage points over the past year.
- Supernus is more profitable, keeping -5.4 cents of every revenue dollar as net income versus -160.6 cents for Arrowhead Pharmaceuticals.
- Supernus grew revenue faster in its latest fiscal year (+8.63% vs -45.65%).
About Arrowhead Pharmaceuticals
ARWR stock →Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States.
Health Care · Biotechnology: Pharmaceutical Preparations · 1,062 employees
About Supernus
SUPN stock →Supernus, Inc., together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and related disorders in the United States, Europe, Canada, Australia, and internationally. It develops medicines to treat substance use disorders.
Health Care · Biotechnology: Pharmaceutical Preparations · 827 employees
ARWR vs SUPN FAQ
Which is bigger, Arrowhead Pharmaceuticals or Supernus?
Supernus (SUPN) is larger, with a market capitalization of $5.94B compared with $5.85B for Arrowhead Pharmaceuticals (ARWR).
Which stock has performed better over the past year, ARWR or SUPN?
ARWR returned +2.27% over the past 12 months, compared with -36.87% for SUPN (price return, excluding dividends). Past performance does not predict future results.
Are Arrowhead Pharmaceuticals and Supernus in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.